DDAVP Challenge in Von Willebrand Disease
Administer 0.3 mcg/kg of DDAVP intravenously over 10 minutes (or 15 mcg subcutaneously for patients >50 kg), then measure VWF:RCo, VWF:Ag, and FVIII:C at baseline, 1 hour, and 4 hours post-infusion to determine therapeutic responsiveness. 1
Timing and Administration
The DDAVP challenge should be performed 30 minutes prior to scheduled procedures when used therapeutically 1. For diagnostic testing purposes:
- Dose: 0.3 mcg/kg IV infused over 10 minutes (standard approach) 1
- Alternative: 15 mcg subcutaneous dose for patients weighing >50 kg achieves equivalent response rates 2
- Route considerations: IV/subcutaneous preferred over intranasal when nasal absorption may be compromised 1
Laboratory Measurements
Essential Time Points
Measure the following parameters at specific intervals:
Baseline (pre-DDAVP):
- VWF:RCo (ristocetin cofactor activity)
- VWF:Ag (von Willebrand factor antigen)
- FVIII:C (factor VIII coagulant activity)
- Bleeding time (optional, less commonly used now)
Post-DDAVP measurements:
- 1 hour: Peak response typically occurs at 90 minutes to 2 hours 1
- 4 hours: Assesses sustained response and durability 3
Response Criteria
Complete response is defined as achieving ALL of the following at 1-4 hours post-DDAVP:
- VWF:RCo ≥0.50 IU/mL (≥50 IU/dL)
- FVIII:C ≥0.50 IU/mL (≥50 IU/dL)
- At least 3-fold increase from baseline 4, 5
Partial response: Significant increase but not meeting all complete response criteria 2
Practical Shortcuts to Reduce Testing Burden
Recent evidence provides cutoffs that can eliminate the need for extensive testing in certain patients 3:
Skip Testing Entirely If:
- Type 1 VWD with baseline VWF:Act ≥0.34 IU/mL - these patients are universally responsive
- Type 2 VWD with baseline VWF:Act ≥0.28 IU/mL - these patients are universally responsive
- Historical lowest VWF:Act ≥0.30 IU/mL - testing not needed 3
Abbreviated Testing Protocol:
For Type 1 VWD patients requiring testing:
- If T1 VWF:Act ≥0.89 IU/mL, response will be sustained at T4 - no need for 4-hour measurement 3
For Type 2 VWD patients requiring testing:
- If T1 VWF:Act ≥1.10 IU/mL, response will be sustained - but still measure T4 to confirm 3
Expected Response Rates by VWD Type
Response rates vary significantly by disease subtype 4:
- Type 1 VWD: 27-82.5% complete response rate (varies by severity) 2, 4
- Type 2A VWD: Only 7% complete response - poor candidates 4
- Type 2M VWD: 14% complete response - generally poor candidates 4
- Type 2N VWD: 75% complete response - good candidates 4
- Type 2B VWD: Contraindicated - can cause thrombocytopenia 6
Critical Caveats
Tachyphylaxis Development
When DDAVP is given on consecutive days, expect approximately 30% reduction in response after the second dose, but no further decline with third and fourth doses 7. Allow 2-3 days between administrations to restore full responsiveness 7.
Age Considerations
DDAVP responsiveness may vary across the female life cycle, particularly around puberty and menopause, though data is limited 8. Consider rechallenging postpubertal females if initial testing was done in childhood.
Monitoring During Repeated Use
When using DDAVP therapeutically (not just for testing), continuously monitor VWF:RCo, FVIII:C, and bleeding time to ensure adequate levels are maintained 1.
Contraindications
- Severe Type 1 VWD with VWF:RCo <10 IU/dL and FVIII:C <20 IU/dL - low response rate 4
- Type 2B VWD - risk of thrombocytopenia
- Type 3 VWD - no endogenous VWF to release
- Factor VIII levels ≤5% - ineffective 1
Enhanced Functional Characterization
Combining VWF:RCo with VWF:CB (collagen binding) provides superior differentiation between VWD subtypes 9:
- Type 1: Good rises in both VWF:CB and VWF:RCo; CB/Ag ratio increases more than RCo/Ag
- Type 2A: Poor absolute rises in both VWF:CB and VWF:RCo; both ratios remain <0.7
- Type 2M: Good rise in VWF:CB but poor rise in VWF:RCo; CB/Ag increases but RCo/Ag stays <0.7
This dual assay approach improves diagnostic accuracy when characterizing DDAVP response patterns 9.